NEW YORK (GenomeWeb News) – Fluidigm said this week it has completed its $207.5 million buy of mass cytometry firm DVS Sciences. Principally operating in Sunnyvale, Calif., DVS is now a wholly owned subsidiary of Fluidigm.
Registering provides access to this and other free content.
Already have an account?Login Now.
In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.
Hong Kong is using DNA phenotyping to shame litterers.
A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.
NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.